Evidence map›Paper›PMID 41142848›Full record

ArticleThe journal of liquid biopsy2025

ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center.

Thais Maloberti, Laura Poppi, Giulia Ciccimara, Sara Coluccelli, Floriana Jessica Di Paola, Giulia Calafato, Viviana Sanza, Elisa Gruppioni, Annalisa Altimari, Sara Quercia and 6 more

Abstract read
In one paragraph

Article in The journal of liquid biopsy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The journal of liquid biopsy · 2026
    Review
  2. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thais MalobertiSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Laura PoppiSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giulia CiccimaraSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Sara ColuccelliSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Floriana Jessica Di PaolaBiobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy.
Giulia CalafatoBiobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy.
Viviana SanzaSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Elisa GruppioniSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Annalisa AltimariSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Sara QuerciaDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Alessandra BernardiDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Claudio ZamagniDivision of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Roberta MinariMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Antonio De LeoSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Giovanni TalliniSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Dario de BiaseSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Activating mutations in the Methods: We analyzed 161 plasma samples from patients with metastatic ER+/HER2- breast cancer who had previously undergone treatment with endocrine therapy and CDK4/6 inhibitors. Results: Twenty-one samples (12.4 %) did not meet the quality criteria for Conclusions:

Indexed as

Breast cancerctDNAESR1Liquid biopsyNGS

Identifiers

PMID41142848
PMCPMC12547707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.